Emergent BioSolutions (EBS) Cash & Equivalents (2010 - 2026)

Emergent BioSolutions' Cash & Equivalents history runs 17 years deep, the most recent figure standing at $160.3 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 7.51% year-over-year to $160.3 million; the TTM figure through Mar 2026 stood at $160.3 million (up 7.51% YoY), while the FY2025 annual figure was $205.4 million, up 106.43% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $160.3 million, down from $205.4 million in the prior quarter.
• The five-year high for Cash & Equivalents was $642.6 million in Q4 2022, with the low at $69.7 million in Q2 2024.
• The 5-year median for Cash & Equivalents is $160.3 million (2026), against an average of $224.8 million.
• The sharpest annual moves came in 2023 and 2025: Cash & Equivalents sank 82.62% in 2023, then jumped 283.5% in 2025.
• Emergent BioSolutions' Cash & Equivalents stood at $642.6 million in 2022, then tumbled by 82.62% to $111.7 million in 2023, then dropped by 10.92% to $99.5 million in 2024, then jumped by 106.43% to $205.4 million in 2025, then declined by 21.96% to $160.3 million in 2026.
• Business Quant data shows EBS's Cash & Equivalents at $160.3 million in Q1 2026, $205.4 million in Q4 2025, and $245.5 million in Q3 2025.